

## **Product datasheet for TL305391V**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### **CHST11 Human shRNA Lentiviral Particle (Locus ID 50515)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

Product Name: CHST11 Human shRNA Lentiviral Particle (Locus ID 50515)

**Locus ID:** 50515

Synonyms: C4ST; C4ST-1; C4ST1; HSA269537; OCBMD

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: CHST11 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

**RefSeq:** NM 001173982, NM 018413, NM 018413.1, NM 018413.2, NM 018413.3, NM 018413.4,

NM 018413.5, NM 001173982.1, BC013315, BC013315.1, BC030271, BC061524, NM 018413.6,

NM 001173982.2

UniProt ID: Q9NPF2

**Summary:** The protein encoded by this gene belongs to the sulfotransferase 2 family. It is localized to

the golgi membrane, and catalyzes the transfer of sulfate to position 4 of the N-

acetylgalactosamine (GalNAc) residue of chondroitin. Chondroitin sulfate constitutes the predominant proteoglycan present in cartilage, and is distributed on the surfaces of many cells and extracellular matrices. A chromosomal translocation involving this gene and IgH, t(12;14)(q23;q32), has been reported in a patient with B-cell chronic lymphocytic leukemia. Alternatively spliced transcript variants encoding different isoforms have been found for this

gene. [provided by RefSeq, Aug 2011]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).